ah-111585 and pazopanib

Angiogenesis is a driver of platinum resistance in ovarian cancer. We assessed the effect of combination pazopanib and paclitaxel followed by maintenance pazopanib in patients with platinum-resistant/refractory ovarian cancer. Integrins α. We conducted an open-label, phase Ib study in patients with platinum-resistant/refractory ovarian cancer. Patients received 1 week of single-agent pazopanib (800 mg daily) followed by combination therapy with weekly paclitaxel (80 mg/m. Fourteen patients were included in the intention-to-treat analysis. Complete and partial responses were seen in seven patients (54%). Median progression-free survival (PFS) was 10.63 months, and overall survival (OS) was 18.5 months. Baseline [. Combination therapy followed by maintenance pazopanib is effective and tolerable in platinum-resistant/refractory ovarian cancer. [

Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Ovarian Neoplasms; Paclitaxel; Peptides; Polyethylene Glycols; Positron-Emission Tomography; Pyrimidines; Sulfonamides